---
title: "CSPC Pharma trustee buys 2,900,000 shares for HK$19.84 million under 2026 share award scheme"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290552646.md"
description: "CSPC Pharma trustee purchased 2.9 million shares for HK$19.84 million under the 2026 share award scheme on June 23, at an average price of HK$6.84 per share. This transaction represents approximately 0.03% of outstanding shares. Trustee holdings under this specific scheme now total 35,828,000 shares (0.31%). A separate trustee for the 2018 scheme holds 117 million shares."
datetime: "2026-06-23T11:04:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290552646.md)
  - [en](https://longbridge.com/en/news/290552646.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290552646.md)
generator: "portal-rs"
---

# CSPC Pharma trustee buys 2,900,000 shares for HK$19.84 million under 2026 share award scheme

-   CSPC Pharmaceutical introduced a 2026 restricted share award scheme. A trustee bought 2,900,000 shares in the market on June 23. \* Average purchase price HK$ 6.84. Total consideration about HK$ 19.84 million, excluding transaction costs. \* The purchase equals about 0.03% of shares outstanding. Trustee holdings under the 2026 scheme rose to 35,828,000 shares, about 0.31%. \* A separate trustee for the 2018 share award scheme holds 117,000,000 shares on trust. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260623-12212143), on June 23, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [300765.CN](https://longbridge.com/en/quote/300765.CN.md)
- [01093.HK](https://longbridge.com/en/quote/01093.HK.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [CSPC PHARMA  1H26 Net Profit Surges Nearly 1.4x, Interim DPS Up 28.6% to HKD0.18](https://longbridge.com/en/news/296435690.md)
- [CSPC Pharma FY26 H1 profit attributable to shareholders more than doubled to RMB 6.09 billion; revenue rises 40.1% to RMB 18.59 billion](https://longbridge.com/en/news/296433558.md)
- [M Stanley Raises CSPC PHARMA  TP to HKD12, Rating Overweight](https://longbridge.com/en/news/296557755.md)
- [CSPC PHARMA  Shares Rise 15% as Phase Ib/II Clinical Trial of SYS 6090 Injection for Hepatocellular Carcinoma Launches at First Center in China](https://longbridge.com/en/news/296423040.md)
- [Chongqing Machinery & Electric proposes interim dividend of RMB 0.02 per share](https://longbridge.com/en/news/296502579.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**